智通财经APP讯,和铂医药-B(02142)发布公告,中国国家药品监督管理局(国家药监局)已受理HBM7004(一款治疗晚期实体瘤的新型B7H4xCD3双特异性抗体)的新药临床试验(IND)申请。诚如本公司日期为2026年5月8日的公告所披露,此乃继本集团近期获美国食品药品监督管理局许可其IND申请,以于美国对HBM7004启动首次人体I期临床试验后取得的又一进展。
智通财经APP讯,和铂医药-B(02142)发布公告,中国国家药品监督管理局(国家药监局)已受理HBM7004(一款治疗晚期实体瘤的新型B7H4xCD3双特异性抗体)的新药临床试验(IND)申请。诚如本公司日期为2026年5月8日的公告所披露,此乃继本集团近期获美国食品药品监督管理局许可其IND申请,以于美国对HBM7004启动首次人体I期临床试验后取得的又一进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.